Vical Shares Down 28.5% After Co. Reported Phase 2 Trial Of HSV-2 Therapeutic Vaccine For Genital Herpes Did Not Meet Primary Endpoint; Co. Announced It Would Be Terminating HSV-2 Program And Will Remain Focused On Antifungal VL-2397